Cost Effectiveness Debate Now Features The Body Bag Argument

 
• By Brenda Sandburg

Center for Medicine in the Public Interest contends that over five years, 44,000 fewer patients will be alive if ICER's cost-effectiveness calculation for multiple myeloma treatments is adopted.

More from Market Access

More from Pink Sheet